Weekly injections for stomach side effects in overweight people
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests two weekly hormone injections (GIP and amylin) to see how they affect stomach-related side effects in people who are overweight or obese. Researchers want to understand if these hormones can help manage weight or related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned female at birth.
- You are between 18 and 64 years old.
- Your body mass index (BMI) is between 27 and 39.9.
- Your excess weight is mostly from body fat (as judged by a doctor).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control if you could become pregnant.
- You have not taken weight-loss drugs or had certain weight-loss surgeries in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This study tests a new weekly injection (called NNC0487-0111) against an existing medicine (semaglutide) to see if it helps people with type 2 diabetes lose more weight. Together with standard diabetes care and lifestyle changes, you would receive the study medicine for about a year, and the study team will monitor your health and weight.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This study tests a weekly injection called tirzepatide to see if it helps people with type 1 diabetes who are overweight or obese. The goal is to improve blood sugar control and help with weight loss.
This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.
This study tests a new injectable medication to help adults with obesity or overweight who don't have diabetes lose weight. It involves a reduced-calorie diet and exercise plan, and may offer an effective treatment option for weight management.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.